Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q21098841> ?p ?o }
Showing triples 1 to 28 of
28
with 100 triples per page.
- Q21098841 subject Q8522216.
- Q21098841 subject Q9052323.
- Q21098841 abstract "LGD-4033 (now known as VK5211) is an investigational selective androgen receptor modulator (SARM) for treatment of conditions such as muscle wasting and osteoporosis, discovered by Ligand Pharmaceuticals and currently under development by Viking Therapeutics.".
- Q21098841 atcPrefix "none".
- Q21098841 casNumber "1165910-22-4".
- Q21098841 fdaUniiCode "1EJT54415A".
- Q21098841 iupacName "4-[(2R)-2-[(1R)-2,2,2-trifluoro-1-hydroxyethyl]pyrrolidin-1-yl]-2-(trifluoromethyl)benzonitrile".
- Q21098841 pubchem "44137686".
- Q21098841 thumbnail LGD-4033.svg?width=300.
- Q21098841 wikiPageWikiLink Q165328.
- Q21098841 wikiPageWikiLink Q22079533.
- Q21098841 wikiPageWikiLink Q7365.
- Q21098841 wikiPageWikiLink Q7447756.
- Q21098841 wikiPageWikiLink Q8522216.
- Q21098841 wikiPageWikiLink Q9052323.
- Q21098841 atcPrefix "none".
- Q21098841 casNumber "1165910".
- Q21098841 iupacName "4".
- Q21098841 pubchem "44137686".
- Q21098841 unii "1".
- Q21098841 type ChemicalSubstance.
- Q21098841 type Drug.
- Q21098841 type ChemicalObject.
- Q21098841 type Thing.
- Q21098841 type Q8386.
- Q21098841 comment "LGD-4033 (now known as VK5211) is an investigational selective androgen receptor modulator (SARM) for treatment of conditions such as muscle wasting and osteoporosis, discovered by Ligand Pharmaceuticals and currently under development by Viking Therapeutics.".
- Q21098841 label "LGD-4033".
- Q21098841 depiction LGD-4033.svg.